Alaunos Therapeutics (TCRT) AI Stock Analysis

• Market Cap: $4.57M
• Dividend Yield: N/A
• Average Volume (3M): 18.58K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.88
• Revenue Growth: 80.00%
• EPS Growth: 86.70%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -2.92
• Shares Outstanding: 1,639,521
• 10 Day Avg. Volume: 10,541
• 30 Day Avg. Volume: 18,581
• PEG Ratio: -0.08
• Price to Book (P/B): 4.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.17
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 131.91
• Enterprise Value/Gross Profit: 454.37
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Alaunos Therapeutics' overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.

Alaunos Therapeutics Business Overview & Revenue Model

Company Description

Alaunos Therapeutics (TCRT) is a biotechnology company focused on the development and commercialization of innovative, cell-based cancer immunotherapies. Operating within the healthcare and biotechnology sectors, the company is committed to advancing its proprietary T-cell receptor (TCR) therapy platform. This platform is designed to harness the power of the body's immune system to target and destroy cancer cells, offering potential treatments for a variety of solid tumor cancers.

How the Company Makes Money

Alaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing deals with larger pharmaceutical companies. These partnerships can include milestone payments and royalties based on the successful development and commercialization of therapies. Additionally, Alaunos may seek funding through private and public investments to support ongoing research and clinical trials, although these do not directly constitute revenue.

Alaunos Therapeutics Financial Statement Overview

Summary

Alaunos Therapeutics faces significant financial challenges with continuous losses, negative cash flows, and a declining equity base. While the absence of debt reduces financial risk, the lack of profitability and need for external funding highlight the company's precarious financial position.

Income Statement

Alaunos Therapeutics has struggled with profitability, evidenced by its negative net income and EBIT margins over recent years. Despite a marginal increase in revenue in the latest year, the company remains unprofitable, with widening losses. The gross profit margin is effectively non-existent due to minimal revenue.

Balance Sheet

The company has a relatively strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, its equity ratio has declined due to shrinking stockholders' equity, which signals potential financial instability. Return on equity is not meaningful due to persistent losses.

Cash Flow

Alaunos Therapeutics reports negative free cash flow, indicating cash outflows from operations continue to exceed cash inflows. Although operating cash flow has improved from previous years, the company still requires substantial external financing to support operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.00K	10.00K	5.00K	2.92M	398.00K	0.00
	Gross Profit
9.00K	10.00K	-4.80M	163.00K	-342.00K	-1.13M
	EBIT
-4.16M	-4.81M	-34.27M	-35.10M	-77.55M	-80.36M
	EBITDA
-4.07M	-4.68M	-30.90M	-31.82M	-74.97M	-78.85M
	Net Income Common Stockholders
-4.07M	-4.68M	-35.14M	-37.60M	-76.89M	-78.85M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.09M	1.09M	6.06M	39.06M	76.05M	115.07M
	Total Assets
2.75M	2.75M	8.26M	64.94M	94.86M	146.34M
	Total Debt
0.00	0.00	0.00	19.51M	29.36M	4.81M
	Net Debt
-1.09M	-1.09M	-6.06M	-19.55M	-46.69M	-110.25M
	Total Liabilities
692.00K	692.00K	1.96M	26.38M	36.81M	22.36M
	Stockholders Equity
2.06M	2.06M	6.31M	38.55M	58.06M	123.98M
Cash Flow		Free Cash Flow
25.85M	-4.97M	-30.34M	-29.45M	-64.79M	-66.79M
	Operating Cash Flow
23.61M	-4.97M	-30.14M	-29.23M	-61.47M	-57.01M
	Investing Cash Flow
0.00	0.00	1.35M	-193.00K	-3.32M	-9.78M
	Financing Cash Flow
-24.95M	0.00	-18.14M	6.37M	25.78M	102.12M

Alaunos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Positive. The current price of 2.69 is below the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.58, and above the 200-day MA of 2.23, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.80 is Neutral, neither overbought nor oversold. The STOCH value of 88.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRT.

Alaunos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
TOVX	45 Neutral	$4.00M	―	-100.01%	―	―	6.87%
TCRT	45 Neutral	$4.57M	―	-139.06%	―	80.00%	86.70%
XBIO	43 Neutral	$4.78M	―	-53.16%	―	-1.56%	5.01%
SONN	41 Neutral	$3.69M	―	-714.96%	―	978.39%	69.65%
OGEN	29 Underperform	$3.16M	―	-748.05%	―	-100.00%	76.55%
WINT	28 Underperform	$2.89M	―	-120.01%	―	―	97.84%

Alaunos Therapeutics Corporate Events

Alaunos Therapeutics Board Opts for Equity Compensation

On April 13, 2025, Alaunos Therapeutics‘ Board of Directors decided to receive their deferred board service fees in equity instead of cash, as per the company’s policy. The deferred fees, totaling $139,000 from late 2024 to early 2025, were compensated with 38,269 shares of common stock and 10,904 stock options, reflecting a strategic move to align the board’s interests with the company’s performance.

Spark’s Take on TCRT Stock

According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.

Alaunos Therapeutics is in a challenging financial position due to ongoing losses and negative cash flows. While technical indicators suggest positive momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock. The absence of debt provides some financial flexibility, but the need for external funding remains a critical concern.

To see Spark’s full report on TCRT stock, click here.